Imprimis Pharmaceuticals Inc (IMMY) 8.60 $IMMY
Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:28PM CST
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals EPS of -$0.27
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:26PM CST
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments
PR Newswire - Wed Nov 12, 3:00PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced financial results for the third quarter ended September 30, 2014, and provided an update on recent business developments.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals to Host its Third Quarter 2014 Financial Report Conference Call and Webcast on November 12, 2014
PR Newswire - Thu Nov 06, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, reported that it will release its third quarter 2014 financial results on Wednesday, November 12, 2014. The company will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on the same day to discuss the third quarter 2014 financial results and recent business development activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless(TM) Proprietary Formulations to Ophthalmologists in Puerto Rico
PR Newswire - Tue Nov 04, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a distribution agreement with MD Distributor, Corp. (MDD). Under the agreement, MDD has the rights to market, sell and distribute Imprimis' patent-pending Go Dropless(TM) formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement also covers the Dominican Republic and countries in the Caribbean once regulatory approvals are obtained. MDD represents leading healthcare companies and its experienced sales and marketing professionals are primarily focused in the specialty areas of ophthalmology and dermatology.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation
PR Newswire - Wed Oct 29, 7:31AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) today announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable by private healthcare providers and to Medicare beneficiaries under CPT Code 51700.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting
PR Newswire - Fri Oct 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago, Illinois. The company also announced Dropless media coverage from AAO meeting, where it introduced a new white paper, titled, "Making Dropless Cataract Surgery Possible".
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals' Dropless Formulations to be Presented in Multiple Sessions at the 2014 American Academy of Ophthalmology (AAO) Meeting
PR Newswire - Thu Oct 16, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of high quality and innovative sterile and topical compounded drug formulations, today announces its attendance, and related "Go Dropless!(TM)" events, at the 2014 American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, October 17-21.
IMMY: 8.60 (+0.08)
Nasdaq stocks posting largest percentage decreases
AP - Thu Sep 25, 12:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
LOXO: 11.45 (-0.06), PSBH: 7.35 (-0.40), EGLT: 6.33 (-0.51), ICEL: 7.59 (-0.05), MSON: 11.66 (-0.17), ATTU: 9.60 (+0.45), HGSH: 4.30 (-0.10), LPCN: 5.29 (+0.34), TKMR: 16.41 (+0.14), DXM: 8.48 (-0.06), IMMY: 8.60 (+0.08), TKM.TO: 18.48 (+0.08)
Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference
PR Newswire - Tue Sep 16, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced that Chief Executive Officer Mark Baum will be a presenter at the 5th Annual Craig-Hallum Alpha Select Conference in New York City. Mr. Baum will discuss the company's growth strategy, including its Go Dropless(TM) campaign in ophthalmology. The presentation is scheduled for 10:40 a.m. EST on Thursday, September 18, 2014 at the Convene Conference Center in New York. An audio portion of this presentation will be broadcast in a live webcast, and an archive of the webcast will be available for 90 days following the event. The webcast and slides for the presentation will be available at http://wsw.com/webcast/ch4/immy/ or on the Investor Relations section of the Imprimis' website at www.imprimispharma.com.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Appoints Healthcare Leader William H. Nelson to its Board of Directors
PR Newswire - Mon Sep 08, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced the appointment of William H. Nelson to its Board of Directors, effective September 4, 2014.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
PR Newswire - Wed Aug 13, 3:30PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients pursuant to prescriptions for individually identified patients at accessible prices, today announced selected financial results for the quarter ended June 30, 2014, and provided an update on recent operations.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals' Go Dropless(TM) Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium
PR Newswire - Thu Jul 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 - 27, 2014.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Go Dropless(TM) Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy
PR Newswire - Tue Jun 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, today unveiled the results of a recent survey1 of leading national cataract surgeons (www.GoDropless.com/why-go-dropless).
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference
PR Newswire - Tue Mar 25, 5:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
PR Newswire - Tue Mar 04, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations
PR Newswire - Wed Feb 19, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this role, House will head the Company's distribution and operations team to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
MCRS: 67.99 (unch), IHG: 40.29 (+0.07), IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting
PR Newswire - Tue Jan 28, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless(TM) campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:28PM CST
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals EPS of -$0.27
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:26PM CST
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments
PR Newswire - Wed Nov 12, 3:00PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced financial results for the third quarter ended September 30, 2014, and provided an update on recent business developments.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals to Host its Third Quarter 2014 Financial Report Conference Call and Webcast on November 12, 2014
PR Newswire - Thu Nov 06, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, reported that it will release its third quarter 2014 financial results on Wednesday, November 12, 2014. The company will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on the same day to discuss the third quarter 2014 financial results and recent business development activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless(TM) Proprietary Formulations to Ophthalmologists in Puerto Rico
PR Newswire - Tue Nov 04, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a distribution agreement with MD Distributor, Corp. (MDD). Under the agreement, MDD has the rights to market, sell and distribute Imprimis' patent-pending Go Dropless(TM) formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement also covers the Dominican Republic and countries in the Caribbean once regulatory approvals are obtained. MDD represents leading healthcare companies and its experienced sales and marketing professionals are primarily focused in the specialty areas of ophthalmology and dermatology.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation
PR Newswire - Wed Oct 29, 7:31AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) today announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable by private healthcare providers and to Medicare beneficiaries under CPT Code 51700.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting
PR Newswire - Fri Oct 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago, Illinois. The company also announced Dropless media coverage from AAO meeting, where it introduced a new white paper, titled, "Making Dropless Cataract Surgery Possible".
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals' Dropless Formulations to be Presented in Multiple Sessions at the 2014 American Academy of Ophthalmology (AAO) Meeting
PR Newswire - Thu Oct 16, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of high quality and innovative sterile and topical compounded drug formulations, today announces its attendance, and related "Go Dropless!(TM)" events, at the 2014 American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, October 17-21.
IMMY: 8.60 (+0.08)
Nasdaq stocks posting largest percentage decreases
AP - Thu Sep 25, 12:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
LOXO: 11.45 (-0.06), PSBH: 7.35 (-0.40), EGLT: 6.33 (-0.51), ICEL: 7.59 (-0.05), MSON: 11.66 (-0.17), ATTU: 9.60 (+0.45), HGSH: 4.30 (-0.10), LPCN: 5.29 (+0.34), TKMR: 16.41 (+0.14), DXM: 8.48 (-0.06), IMMY: 8.60 (+0.08), TKM.TO: 18.48 (+0.08)
Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference
PR Newswire - Tue Sep 16, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced that Chief Executive Officer Mark Baum will be a presenter at the 5th Annual Craig-Hallum Alpha Select Conference in New York City. Mr. Baum will discuss the company's growth strategy, including its Go Dropless(TM) campaign in ophthalmology. The presentation is scheduled for 10:40 a.m. EST on Thursday, September 18, 2014 at the Convene Conference Center in New York. An audio portion of this presentation will be broadcast in a live webcast, and an archive of the webcast will be available for 90 days following the event. The webcast and slides for the presentation will be available at http://wsw.com/webcast/ch4/immy/ or on the Investor Relations section of the Imprimis' website at www.imprimispharma.com.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Appoints Healthcare Leader William H. Nelson to its Board of Directors
PR Newswire - Mon Sep 08, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced the appointment of William H. Nelson to its Board of Directors, effective September 4, 2014.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
PR Newswire - Wed Aug 13, 3:30PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients pursuant to prescriptions for individually identified patients at accessible prices, today announced selected financial results for the quarter ended June 30, 2014, and provided an update on recent operations.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals' Go Dropless(TM) Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium
PR Newswire - Thu Jul 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 - 27, 2014.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Go Dropless(TM) Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy
PR Newswire - Tue Jun 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, today unveiled the results of a recent survey1 of leading national cataract surgeons (www.GoDropless.com/why-go-dropless).
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference
PR Newswire - Tue Mar 25, 5:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
PR Newswire - Tue Mar 04, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations
PR Newswire - Wed Feb 19, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this role, House will head the Company's distribution and operations team to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
MCRS: 67.99 (unch), IHG: 40.29 (+0.07), IMMY: 8.60 (+0.08)
Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting
PR Newswire - Tue Jan 28, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless(TM) campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
IMMY: 8.60 (+0.08)
